MARKET

GKOS

GKOS

Glaukos
NYSE

Real-time Quotes | Nasdaq Last Sale

32.61
+2.09
+6.85%
After Hours: 32.62 +0.01 +0.04% 16:11 04/08 EDT
OPEN
30.83
PREV CLOSE
30.52
HIGH
33.89
LOW
30.44
VOLUME
526.06K
TURNOVER
--
52 WEEK HIGH
84.65
52 WEEK LOW
23.31
MARKET CAP
1.43B
P/E (TTM)
372.26
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 10 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average GKOS stock price target is 47.13 with a high estimate of 62.00 and a low estimate of 34.00.

EPS

GKOS News

More
  • Wells Fargo Maintains Underweight on Glaukos, Lowers Price Target to $34
  • Benzinga · 16h ago
  • Glaukos (GKOS) Down 45.8% Since Last Earnings Report: Can It Rebound?
  • Zacks · 03/28 15:30
  • Glaukos Provides COVID-19 Pandemic Update
  • Business Wire · 03/24 14:00
  • Edited Transcript of GKOS earnings conference call or presentation 27-Feb-20 9:30pm GMT
  • Thomson Reuters StreetEvents · 03/23 17:27

Industry

Medical Equipment, Supplies & Distribution
+4.22%
Healthcare Equipment & Supplies
+4.03%

Hot Stocks

Symbol
Price
%Change

About GKOS

Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm's canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream. It is developing three additional pipeline products: the iStent Inject, the iStent Supra and iDose. The iStent Inject includes two stents pre-loaded in an auto-injection inserter. The iStent Supra is designed to access an alternative drainage space within the eye. iDose is a drug delivery system that is designed to be implanted in the eye to continuously deliver therapeutic levels of medication for extended periods of time to lower intraocular pressure in glaucoma patients.
More

Webull offers kinds of Glaukos Corp stock information, including NYSE:GKOS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GKOS stock news, and many more online research tools to help you make informed decisions.